Last reviewed · How we verify
INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
At a glance
| Generic name | INSULIN SUSP ISOPHANE RECOMBINANT HUMAN |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
Key clinical trials
- Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method (NA)
- Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30 (PHASE1)
- Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N (PHASE1)
- Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INSULIN SUSP ISOPHANE RECOMBINANT HUMAN CI brief — competitive landscape report
- INSULIN SUSP ISOPHANE RECOMBINANT HUMAN updates RSS · CI watch RSS